Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 9/20 | 0.36 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2344237 | 0.85 | DGAT1 (0.38) | DGAT1KLKB1 | |
| SCHEMBL2346604 | 0.85 | DGAT1 (0.36) | DGAT1KLKB1MAPT | |
| SCHEMBL12402542 | 0.85 | DGAT1 (0.36) | DGAT1KLKB1MAPT | |
| SCHEMBL650307 | 0.85 | DGAT1 (0.42) | DGAT1KLKB1MAPT | |
| SCHEMBL1634123 | 0.85 | DGAT1 (0.36) | DGAT1KLKB1 | |
| SCHEMBL12372355 | 0.81 | DGAT1 (0.42) | DGAT1KLKB1MAPT | |
| SCHEMBL1891747 | 0.80 | DGAT1 (0.34) | DGAT1KLKB1 | |
| SCHEMBL1635721 | 0.80 | DGAT1 (0.37) | DGAT1MAPT | |
| SCHEMBL12661421 | 0.79 | DGAT1 (0.33) | DGAT1MAPT | |
| SCHEMBL13689597 | 0.79 | DGAT1 (0.35) | DGAT1KLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902197-B2 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2011-03-08 | — | — | US | disclosed |
| US-7902197-B2 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2011-03-08 | — | — | US | disclosed |
| US-7902197-B2 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2011-03-08 | — | — | US | disclosed |
| EP-2250172-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2010-11-17 | — | — | EP | disclosed |
| WO-2009106443-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-03 | — | — | WO | disclosed |
| US-20090215788-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2009-08-27 | — | — | US | disclosed |
| US-20090215788-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2009-08-27 | — | — | US | disclosed |
| US-20090215788-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215788-A1 | Pyrrolopyrazine kinase inhibitors | SYK, ZAP70, JAK2 | DGAT1 4730/4885KLKB1 2373/4885MAPT 3705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.